Novartis

News

EMA reviewing Novartis' Adakveo after phase 3 miss

The EMA's human medicines committee has started a review of Novartis' sickle cell disease (SCD) therapy Adakveo, shortly after the company reported that it failed to show efficacy in a phas

News

Sandoz bulks up with Mycamine ahead of spin-off

With a separation from parent company Novartis now confirmed, Sandoz has moved to strengthen its revenue base with the acquisition of global rights to mainstay antifungal drug Mycamine from

R&D

Novartis’ Kesimpta, ECTRIMS 2022, and relapsing multiple scl...

Having presented new data at last year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting – where the safety and efficacy of Novartis’ Kesimpta (

News

Free access to Zolgensma curbed, says Novartis

Novartis' programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company.

News

Novartis licenses cocaine use disorder therapy to Stalicla

Swiss biotech Stalicla has continued to diversify its pipeline from a focus on autism therapies with a deal to license Novartis' mavoglurant, in clinical trials for cocaine use disorder (CU

News

Novartis agrees $245m settlement over Exforge generics delay

Novartis has said it will pay $245 million to resolve civil litigation in the US, which accuses it of a 'pay for delay' scheme involving generics of its high blood pressure therapy Exforge.

EMA reviewing Novartis' Adakveo after phase 3 miss

Sandoz bulks up with Mycamine ahead of spin-off

Novartis’ Kesimpta, ECTRIMS 2022, and relapsing multiple scl...

Free access to Zolgensma curbed, says Novartis

Novartis licenses cocaine use disorder therapy to Stalicla

Novartis agrees $245m settlement over Exforge generics delay

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Novartis

Editor's Picks